RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥3,142 | ¥3,715 | ¥3,675 | ¥2,345 |
| Short-Term Investments | ¥200 | ¥50 | ¥251 | ¥314 |
| Receivables | ¥689 | ¥603 | ¥602 | ¥1,205 |
| Inventory | ¥168 | ¥148 | ¥9 | ¥11 |
| Other Curr. Assets | ¥147 | ¥186 | ¥87 | ¥22 |
| Total Curr. Assets | ¥4,539 | ¥4,957 | ¥4,822 | ¥4,004 |
| Property Plant & Equip (Net) | ¥529 | ¥574 | ¥391 | ¥299 |
| Goodwill | ¥3,865 | ¥0 | ¥0 | ¥0 |
| Intangibles | ¥37 | ¥30 | ¥24 | ¥34 |
| Long-Term Investments | ¥547 | ¥1,231 | ¥737 | ¥574 |
| Tax Assets | ¥78 | ¥0 | -¥737 | ¥314 |
| Other NC Assets | ¥60 | ¥80 | ¥1,020 | ¥9 |
| Total NC Assets | ¥5,117 | ¥1,915 | ¥1,436 | ¥1,230 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥9,655 | ¥6,872 | ¥6,258 | ¥5,234 |
| Liabilities | – | – | – | – |
| Payables | ¥59 | ¥54 | ¥128 | ¥46 |
| Short-Term Debt | ¥513 | ¥13 | ¥3 | ¥22 |
| Tax Payable | ¥28 | ¥20 | ¥31 | ¥118 |
| Deferred Revenue | ¥0 | ¥0 | ¥0 | ¥294 |
| Other Curr. Liab. | ¥546 | ¥239 | ¥289 | -¥63 |
| Total Curr. Liab. | ¥1,187 | ¥389 | ¥494 | ¥401 |
| LT Debt | ¥2,651 | ¥39 | ¥9 | ¥0 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥12 |
| Deferred Tax Liab, NC | ¥0 | ¥58 | ¥3 | ¥16 |
| Other NC Liab. | ¥27 | ¥71 | ¥87 | ¥12 |
| Total NC Liab. | ¥2,897 | ¥363 | ¥267 | ¥46 |
| Other Liabilities | ¥0 | -¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥288 | ¥316 | ¥211 | ¥39 |
| Total Liabilities | ¥4,085 | ¥752 | ¥761 | ¥446 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥2,721 | ¥2,668 | ¥2,266 | ¥2,257 |
| Retained Earnings | -¥46 | ¥449 | ¥773 | ¥50 |
| AOCI | -¥15 | ¥146 | ¥3 | ¥35 |
| Other Equity | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Equity | ¥5,571 | ¥6,120 | ¥5,497 | ¥4,788 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥9,655 | ¥6,872 | ¥6,258 | ¥5,234 |
| Net Debt | ¥22 | -¥3,663 | -¥3,664 | -¥2,324 |